LRRK2‐PD has an almost indistinguishable clinico‐pathological phenotype from sporadic PD regarding age of onset, the presence of Lewy bodies (although a minority of cases have been reported without Lewy bodies) 5 and responsiveness to dopamine replacement therapy. This evidence concerns the gene LRRK2 and Parkinson disease.